Benign Prostat Hiperplazisinde Alfa BlokörKullanımı ve Cinsel Fonksiyonlar

Hoesl CE, Woll EM, Burkart M, Altwein JE. Erectile disfunction (ED) is prevalent, bothersome and underdiagnosed in patients con- sulting urologists for benign prostatic syndrome(BPS). Eur Urol 2005; 47:511-517.

Braun M, Wassmer G, Klotz T, Reifenrath B, Mathers M, Engel- mann U. Epidemiology of erectile dysfunction: results of the ‘Co- logne Male Survey’. Int J Impot Res 2000;12:305-311.

El-Sakka AI. Lower urinary tract symptoms in patients with erectile dysfunction: Analysis of risk factors. J Sex Med 2006; 3: 144-149.

McVary K. Lower urinary tract symptoms and sexual dysfun- ction: Epidemiology and pathophysiology. BJU Int 2006;97(2 suppl):23-28.

Demir O, Ozdemir I, Bozkurt O, Aslan G, Esen A. The effect of α-blocker therapy on erectile functions in patients with lower uri- nary tract symptoms due to benign prostate hyperplasia. Asian J of Androl 2009; 11: 716–722

Kirby RS, O’Leary MP, Carson C. Efficacy of extended-release doxazosin and doxazosin standard in patients with concomitant benign prostatic hyperplasia and sexual dysfunction. BJU Int. 2005; 95: 103–109.

James D. Brooks, MD: Anatomy of the lower urinary tract and male genitalia. Campbell’s Urology. Edited by Walsh PC, Retik AB, Vau- ghan ED, Wein AJ. Eighth Edition W.B. Saunders Company. Vol. 1: 41-81, Philadelphia,2002.

Moore KL. The developing human: Clinically Oriented Embryo- logy. 4th edition, W.B. Saunders Company. 68-70,1998.

Shapiro E. Embryologic development of the prostate. Urol Clin North Am 1990; 17: 487-494.

Tanagho EA. Anatomy of the lower urinary tract. Campbell’s Uro- logy (Walsh PC, Retik AB, Stamey TA, Vaughan ED, ed). Sixth edi- tion. Philadelphia, Saunders. Vol 1, 40-69 1992

McNeal JE. Regional morphology and pathology of the prostate. Am J Clin Pathol 1968; 49: 347-357.

Baydinç C.,Beytur A.Ürogenital Organların Anatomik ve Histolojik Yapısı. Temel Üroloji. Anafarta K.,Bedük Y.,Arıkan N., ed.Dördün- cü Baskı. Bölüm 1:1-20,2011

Dixon JS, Gosling JA. Macro-anatomy of the prostate. (Kirby R, Connel JD, Fitzpatrick JM, Roehrborn CG, Boyle P) Textbook of BPH, First edition, Oxford/England. Chapt.1: 3-10,1996

Sigman M, Jarow JP: Male Infertility. Campbell’s Urology. Edited by Walsh PC, Retik AB, Vaughan ED, Wein AJ. Eighth Edition W.B. Saunders Company, Vol.2: 1475-1481, Philadelphia,2002.

AUA Practice Guidelines Committe: AUA guideline on manage- ment of benign prostatic hyperplasia(2003). Chapter 1: diagnosis and treatment recommendations. J Urol, 2003; 170: 530-547.

Aktaş A., Çevik İ.Benign Prostat Hiperplazisi . Temel Üroloji. Ana- farta K.,Bedük Y.,Arıkan N., ed.Dördüncü Baskı. Bölüm 17: 915- 934.2011

Berry SJ, Coffey DS, Walsh PC, et al. The development of human benign prostatic hyperplasia with age. J Urol 1984; 132:474-479.

Garraway WM, Collins GN, Lee RJ. High prevalence of benign prostatic hypertrophy in the community. Lancet 1991; 338:469-471.

Lytton B, Emery Jm, Harvard BM. The incidence of benign prosta- tic hyperplasia. J Urol 1968; 99: 639-45.

Ozturk A, Serel TA, Kosar A, Kecelioglu M. Prevalence of benign hypertrophy of the prostate in Turkish men hospitalized in urology. Prog Urol 2000; 10: 568-570.

Darras FS, Lee C, Huprikar S, Rademaker AW. Evidence for a no- nandrogenic role of testis and epididimis in androgen supported growth of the rat ventral prostate. J Urol 1993; 153:2023-2030.

McConnell JD. Prostatic growth: New insights into hormonal regu- lation. Br J Urol. 1995;76.

Claus G, McConnell JD. Benign prostat hiperplazisinin etiyoloji- si, patofizyolojisi, epidemiyolojisi ve doğal seyri. Campbell Üroloji 8.baskı. Walsh PC, Retik AB, Vaughan ED, Wein AJ. Güneş Kitabevi Ltd.Şti. Ankara Cilt 2: 1297-1336, 2005.

Kerr, JFR, Searle, J. Deletion of Cells by Apoptosis During Castrati- on Induced Involution in the Rat Prostate, Virchows Arch B 1973; 13.

Partin A, et al, Influence of age and endocrine factors on the volume of benign prostatic hyperplasia. J Urol. 1991; 145: 405-409.

Cunha CR, Chung LW, Shannon JM. Hormone induced morphoge- nesis and growth: role of mesenchymal epithelial interactions. Re- cent Prog Horm Res 1983; 39: 559-598.

Silver RL, Wiley, EI, Davis DL, Thipgen AE,Russell DW, McConnell JD. Expresion and regulation of steroid 5-alpha reductase 2 in prostate disease. J Urol 1994; 152: 433-437.

Steiner MS. Review of peptide growth factors in Benign Prostatic Hyperplasia and Urological Malignancy. J Urol 1995; 153: 1085- 1096.

Shapiro E, Hartanto V, Lepor H. Quantifying the smooth muscle content of the prostate using double-immunoenzymatic staining and color asisting image analysis. J Urol 1992; 147: 1167-1172.

Caine M. Reflections on alpha-blocker therapy for benign prostate hyperplasia. Brit J Urol. 1995; 75: 265.

Kobayashi S, Tang R, Shapiro E, et al. Characterization of human alpha-1 adrenoceptor binding sites using radioligand receptor bin- ding on slidemounted tissue sections. J Urol.1993;150:2002-2006.

Schwınn DA. The role of α1-adrenergic receptor subtypes in lower urinary tract symptoms. BJU International. 2001;88(Suppl 2):27- 34.

McConnell JD, Barry MJ, Bruskewitz RC. Benign Prostatic Hyperp- lasia: Diagnosis and treatment. Clinical Practice Guideline. AHCPR Publication No:8. : 36-42. 1994.

Herbert L,Franklin CL. Benign prostat hiperplazisinin değerlendi- rilmesi ve cerrahi olmayan tedavisi. Campbell Üroloji 8.baskı. Wal- sh PC, Retik AB, Vaughan ED, Wein AJ. Güneş Kitabevi Ltd.Şti., Ankara. Cilt 2: 1337-1378, 2005.

Ezz el Din K, Kiemeney LA, de Wildt MJ, Debruyne FM, de la Ro- sette JJ.: Correlation between uroflowmetry, prostate volume, post- void residue and lower urinary tract symptoms as measured by the International Prostate Symptom Score. Urology 1996; 48: 393-397.

Roehrborn CG: Benign prostatic hyperplasia: Updated guidelines and new perspectives. Am J Urol 2004; 2 (suppl 3): 4-13,

Polusen AL, Schou J, Puggard L, Torp-Pedersen S: Prostatic enlar- gement symptomatology and pressure flow evaluation: interrelati- ons in patient with symptomatic BPH. Scand J Urol Nephrol 1994; 157: 67-73.

Abrams P, Griffiths D, Höfner, et al: The urodynamic assessment of lower urinary tract symptoms (Committee 7): In: Chatalein C, Denis L, Foo K, Khoury S, McConnel J (eds). Proceeding of 5th International Consultation on Benign Prostatic Hyperplasia. 2001; 227-281.

Arıkan N. Ürodinamik İncelemeler. Güneş Kitabevi, 145-162, 1990.

Novara G, Galfano A, Gardi M, Ficarra V, Boccon-Gibod L, Artiba- ni W: Critical Review of Guidelines for BPH Diagnosis and Treatment Strategy .European Urology Supplements 2006; 5: 418–429.

Andersson KE, Lepor H, Wyllie MG. Prostatic α1-adrenoreceptors and uroselectivity. Prostate 1997; 30: 202-215.

Caine M, Pfau A, Perlberg S. The use of alpha-adrenergic blockers in benign prostatic obstruction. Br J Urol 1976; 48: 255-263.

Caine M. The present role of alpha-adrenergic blockers in the treat- ment of benign prostatic hypertrophy. J Urol 1986;136:1-4.

Lepor H and the Multicenter Study Group. Long-term efficacy and safety of terazosin in patients with benign prostatic hyperplasia. Urology 1995; 45: 406-413.

Jardin A, Bensadoun H, Delauche-Cavallier MC, et al. Long term treatment of benign prostatic hypertrophy with alfuzosin: A 12-18 months assessment. Br J Urol 1993; 72: 615-621.

Lukacs B, Blondin P, MacCarthy C, et al. Safety profile of 3 mont- hs therapy with alfuzosin in 13.389 patients suffering from benign prostatic hypertrophy. Eur Urol 1996; 29: 29-32.

Buzelin JM, Geffriaud-Ricouard C, Delauche-Cavallier MC, et al. A double-blind placebo controlled trial of sustained-release alfu- zosin in syptomatic benign prostatic hyperplasia. J Urol 1995;153 (suppl):274-278.

Höfner K, Jones U: Alfuzosin : a clinically uroselective alpha-1 blo- cker . World J Urol 2002; 19: 405-412.

Annemans I, Cleemput I, Lamotte M, McNeill A, Hargreave T: The economic impact of using alfuzosin 10mg once daily in the mana- gement of acute urinary retention in the UK: a 6- month analysis. BJU Int. 2005; 4: 566-571.

McVary KT.: Alfuzosin for symptomatic prostatic hyperplasia: Long-term experience. J Urology 2006; 1: 35-42.

McVary KT. Erectile dysfunction and lower urinary tract symptoms secondary to BPH. Eur Urol 2005; 47: 838–845.

Michel CM, Chapple CR: Comparison of the cardiovascular effects of tamsulosin oral controlled absorption system (OCAS) and alfu- zosin prolonged release (XL). Eur Urol 2006; 49: 501-509.

Andersen JT, Ekman P, Wolf H, et al. Can finasteride reverse the progress of benign prostatic hyperplasia? A two year placebocont- rolled study. The Scandinavian BPH study group. Urology. 1995; 46: 631-637.

Vaughan D, Imperato-McGinley J, McConnell J, et al. Long term (7 to 8- year) experience with finasteride in men with benign prostatic hyperplasia. Urology. 2002; 60(6):1040-1046.

Boyle P, Gould AL, Roehrborn CG. Prostate volume predicts the outcome of treatment of benign prostatic hyperplasia with finaste- ride: Meta-analysis of randomised clinical trials. Urology. 1996;48: 398-405.

Marberger MJ, Andersen JT, Nickel JC, et al. Prostate volume and serum prostate-specific antigen as predictors of acute urinary re- tention. Combined experience from three large multinational pla- cebo-controlled trials. Eur Urology. 2000;38: 563-568.

Andersen JT, Nickel JC, Marshall VR, et al. Finasteride significant- ly reduces acute urinary retention and need for surgery in patients with symptomatic benign prostatic hyperplasia. Urology. 1997;49: 839-845.

Bruskewitz R, Girman CJ, Fowler J, et al. Effect of finasteride on bother and other Health-Related Quality of Life Aspects Associated with Benign Prostatic Hyperplasia. PLESS Study Group. Proscar long-term efficacy and safety study. Urology. 1999; 4: 670-678.

Oesterling JE, Roy J, Agha A, et al. Biologic variability of prostate specific antigen and its usefullness as a marker for prostate cancer: Effects of finasteride. The Finasteride PSA Study Group. Urology. 1997;50: 13-18.

Bartsch G, Rittmaster RS, Klocker H. Dihydrotestosterone and the concept of 5 alpha-reductase inhibition in human benign prostatic hyperplasia. World J Urol. 2002;19: 413-425.

Roehborn CG, Boyle PJ, Nickel C, et al. Efficacy and safety of a dual inhibitor or 5-alpha-reductase types 1 and 2 (dutasteride) in men with benign prostatic hyperplasia. Urology. 2002;60: 434-441.

Andriole GL, Kirby R. Safety and tolerability of the Dual 5 alpha-re- ductase inhibitor dutasteride in the treatment of benign prostatic hyperplasia. Eur Urol. 2003;44: 82-88.

Boyle P, Robertson C, Lowe F. Updated metaanalysis of clinical tri- als of Serenoa repens extract in the treatment of symptomatic be- nign prostatic hyperplasia. BJU International 2004; 93: 751-756.

Buck AC. Phytotherapy fort he prostate. BJU International 1996; 78:325-336.

Bayne CW, Donnelly F, Ross M. Serenoa repens : a 5 alpha reduc- tase Tip 1 and 2 inhibitor- new evidence in a coculturel model of BPH. Prostate 1999; 40:232-241.

Nudell DM, Cattolica EV. Transurethral Prostatectomy: An update. AUA Update series, 2000; 19(5): 34-39.

Özdiler E. Endoüroloji ve Girişimsel Üroradyoloji – Transüretral Rezeksiyon ve Diğer Transüretral Yöntemler. Temel Üroloji. Ana- farta K.,Bedük Y.,Arıkan N., ed.Dördüncü Baskı. Bölüm 17:273- 286.2011

Fitzpatrick JM, Mebust WK: Transurethral Prostatectomy. Cam- pbell’s Urology (Walsh PC, Retik AB, Wein, Vaughan ED Jr, ed). Eighth edition. Philadelphia, Saunders. Vol 2, Sect. 6, Chapt. 40, 1402-1412,2002.

Rassweiler J, Teber D, Kuntz R, Hofmann R. Complications of the Transurethral resection of the prostate (TURP)- Incidence, Mana- gement and Prevention. Eur Urol 2005;12:42.

Madersbacher S, Marberger M. Is transurethral resection of the prostate stil justified? BJU Int1999; 83: 227-237.

Merier DE,Tarpley JL, Imediegwa OO. The outcome of suprapubic prostatectomy: a contemporary series in the developing world. Uro- logy 1995; 46: 40-44.

Richard F, Lukacs B, Jardin A, et al: Results of an epidemiological survey in 3,500 French men aged 50 to 80 years with a special atten- tion to urinary symptoms, quality of life and sexual function [abst- ract]. Eur Urol 2000; 37(suppl 2): 10.

Rosen R, Altwein J, Boyle P, Kirby RS, Lukacs B, Meuleman E, O’Leary MP, Puppo P, Robertson C, Giuliano F. Lower urinary tract symptoms and male sexual dysfunction: The multinational survey of the aging male (MSAM-7). Eur Urol 2003;44: 637-649.

Gacci M, Eardley I, Giuliano F, Hatzichristou D, Kaplan SA, Maggi M, McVary K, Mirone V, Porst H, Roehrborn CG. Critical Analysis of the Relationship Between Sexual Dysfunctions and Lower Uri- nary Tract Symptoms Due to Benign Prostatic Hyperplasia. Eur Urol (in press) 2011 June; available from: URL: http://www.europe- anurology.com/article /S0302-2838(11)00673-7/fulltext

McVary KT, Monnig W, Camps Jr JL, Young JM, Tseng L-J, Van Den Eeden G. Sildenafil citrate improves erectile function and urinary symptoms in men with erectile dysfunction and lower urinary tract symptoms associated with benign prostatic hyperplasia: a randomi- zed double-blind trial. J Urol 2007;177:1071–1077.

McVary KT, Roehborn C, Kaminetsky J, et al. Tadalafil relieves lower urinary tract symptoms (LUTS) secondary to benign prosta- tic hyperplasia (BPH). J Urol 2007;177:1401–1407.

Stief CG, Porst H, Neuser D, Beneke M, Ulbrich E. A randomised, placebo-controlled study to assess the efficacy of twice-daily varde- nafil in the treatment of lower urinary tract symptoms secondary to benign prostatic hyperplasia. Eur Urol 2008;53: 1236–1244.

Bechara A, Romano S, Casabe´ A, et al. Comparative efficacy as-sessment of tamsulosin vs. tamsulosin plus tadalafil in the tre- at-ment of LUTS/BPH. Pilot study. J Sex Med 2008;5:2170–2178.

Gacci M, Vittori G, Siena G, et al. Long term safety and efficacy of combination therapy with vardenafil 10 mg and tamsulosin 0,4 mg for persistent irritative LUTS: a randomized double blind placebo controlled study. Eur Urol Suppl 2011;10: 123.

Kaplan SA, Gonzalez RR, Te AE. Combination of alfuzosin and sil- denafil is superior to monotherapy in treating lower urinary tract symptoms and erectile dysfunction. Eur Urol 2007;51: 1717-1723.

AUA guideline on management of benign prostatic hyperplasia (2003). Chapter 1: diagnosis and treatment recommendations. AUA Practice Guidelines Committee. J Urol 2003;170:530–547.

Kobayashi K, Masumori N, Hisasue S, et al. Inhibition of seminal emission is the main cause of anejaculation induced by a new highly selective alpha 1A-blocker in normal volunteers. J Sex Med 2008; 5: 2185–2190.

Hisasue SI, Furuya R, Itoh N, et al. Ejaculatory disorder induced by alpha–adrenergic receptor blockade is not retrograde ejaculation. J Urol 2005;173(Suppl)(290):A1069.

Hellstrom WJG, Sikka SC. Effects of acute treatment with tamsulo- sin versus alfuzosin on ejaculatory function in healthy volun- teers. J Urol 2006;76:1529–1533.

Van Dijk MM, De La Rosette JJ, Michel MC. Effects of alpha 1 ad- renoceptor antagonists on male sexual function. Drugs 2006; 66: 287–301.

Kumar R, Nehra A, Jacobson DJ, et al. Alpha blocker use is asso- ciated with decreased risk of sexual dysfunction. Urology 2009;74: 82–87.

Kirby RS, O’Leary MP, Carson C. Efficacy of extended-release doxazosin and doxazosin standard in patients with concomitant benign prostatic hyperplasia and sexual dysfunction. BJU Int. 2005; 95: 103–109.

Van Moorselaar RJA, Hartung R, Emberton M et al. Alfuzosin 10 mg once daily improves sexual function in men with lower urinary tract symptoms and concomitant sexual dysfunction. BJU Int. 2005; 95: 603–608.

Traish A, Kim NN, Moreland RB, Goldstein I. Role of alpha adre- nergic receptors in erectile function. Int J Impot Res 2000;12 (Suppl 1): 48–63.

Seo KK, Lee MY, Lim SW, Kim SC. Comparison of relaxation responses of cavernous and trigonal smooth muscles from rabbits by alpha1-adrenoceptor antagonists; prazosin, terazosin, doxazo- sin, and tamsulosin. J Korean Med Sci 1999; 14: 69–74.

Rosen R, Giuliano F, Carson CC. Sexual dysfunction and lower urinary tract symptoms (LUTS) associated with benign prostatic hyperplasia (BPH). Eur Urol 2005; 47: 824-830.

Kushiro T, Takahashi A, Saito F, Otsuka Y, Soma M, et al. Erectile dysfunction and its influence on quality of life in patients with es- sential hypertension. Am J Hypertens 2005; 18: 427–430.